Literature DB >> 31243857

Contribution to colonic polyposis of recently proposed predisposing genes and assessment of the prevalence of NTHL1- and MSH3-associated polyposes.

Mariona Terradas1,2, Pau M Munoz-Torres1,2, Sami Belhadj1,2, Gemma Aiza1,2,3, Matilde Navarro1,3, Joan Brunet1,3,4, Gabriel Capellá1,2,3, Laura Valle1,2,3.   

Abstract

Technological advances have allowed the identification of new adenomatous and serrated polyposis genes, and of several candidate genes that require additional supporting evidence of causality. Through an exhaustive literature review and mutational screening of 177 unrelated polyposis patients, we assessed the involvement of MCM9, FOCAD, POLQ, and RNF43 in the predisposition to (nonserrated) colonic polyposis, as well as the prevalence of NTHL1 and MSH3 mutations among genetically unexplained polyposis patients. Our results, together with previously reported data and mutation frequency in controls, indicate that: MCM9 and POLQ mutations are not associated with polyposis; germline RNF43 mutations, with a prevalence of 1.5-2.5% among serrated polyposis patients, do not cause nonserrated polyposis; MSH3 biallelic mutations are highly infrequent among European polyposis patients, and the prevalence of NTHL1 biallelic mutations among unexplained polyposes is ~2%. Although nonsignificant, FOCAD predicted deleterious variants are overrepresented in polyposis patients compared to controls, warranting larger studies to provide definite evidence in favor or against their causal association with polyposis predisposition.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  FOCAD; MCM9; MSH3; NTHL1; POLQ; RNF43; adenomatous polyposis; genetic predisposition; hereditary cancer

Mesh:

Substances:

Year:  2019        PMID: 31243857     DOI: 10.1002/humu.23853

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  8 in total

Review 1.  Multi-Gene Panel Testing in Gastroenterology: Are We Ready for the Results?

Authors:  Flávio Pereira; Manuel R Teixeira; Mário Dinis Ribeiro; Catarina Brandão
Journal:  GE Port J Gastroenterol       Date:  2021-02-04

Review 2.  Intestinal and extraintestinal neoplasms in patients with NTHL1 tumor syndrome: a systematic review.

Authors:  S H Beck; A M Jelsig; H M Yassin; L J Lindberg; K A W Wadt; J G Karstensen
Journal:  Fam Cancer       Date:  2022-03-16       Impact factor: 2.375

Review 3.  How many is too many? Polyposis syndromes and what to do next.

Authors:  Nina Gupta; Christine Drogan; Sonia S Kupfer
Journal:  Curr Opin Gastroenterol       Date:  2022-01-01       Impact factor: 3.287

Review 4.  Hereditary or Not? Understanding Serrated Polyposis Syndrome.

Authors:  Peter P Stanich; Rachel Pearlman
Journal:  Curr Treat Options Gastroenterol       Date:  2019-12

5.  Potential Involvement of NSD1, KRT24 and ACACA in the Genetic Predisposition to Colorectal Cancer.

Authors:  Isabel Quintana; Pilar Mur; Mariona Terradas; Sandra García-Mulero; Gemma Aiza; Matilde Navarro; Virginia Piñol; Joan Brunet; Victor Moreno; Rebeca Sanz-Pamplona; Gabriel Capellá; Laura Valle
Journal:  Cancers (Basel)       Date:  2022-01-29       Impact factor: 6.639

6.  Germline variant testing in serrated polyposis syndrome.

Authors:  Aisling Murphy; Joyce Solomons; Peter Risby; Jessica Gabriel; Tina Bedenham; Michael Johnson; Nathan Atkinson; Adam A Bailey; Elizabeth Bird-Lieberman; Simon J Leedham; James E East; Sujata Biswas
Journal:  J Gastroenterol Hepatol       Date:  2022-02-18       Impact factor: 4.369

Review 7.  The Inherited and Familial Component of Early-Onset Colorectal Cancer.

Authors:  Maria Daca Alvarez; Isabel Quintana; Mariona Terradas; Pilar Mur; Francesc Balaguer; Laura Valle
Journal:  Cells       Date:  2021-03-23       Impact factor: 6.600

8.  Caught in motion: human NTHL1 undergoes interdomain rearrangement necessary for catalysis.

Authors:  Brittany L Carroll; Karl E Zahn; John P Hanley; Susan S Wallace; Julie A Dragon; Sylvie Doublié
Journal:  Nucleic Acids Res       Date:  2021-12-16       Impact factor: 19.160

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.